Who Owns Beam Therapeutics Company?

Beam Therapeutics Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Beam Therapeutics?

Understanding a company's ownership is key to its strategic path. For Beam Therapeutics, a biotech firm focused on precision genetic medicines, its IPO marked a significant shift in its stakeholder landscape.

Founded in 2017 by pioneering scientists, Beam Therapeutics aims to offer lifelong cures for genetic diseases through its innovative base editing technology. This approach seeks to correct mutations without the DNA breaks associated with other gene-editing methods.

As of July 23, 2025, Beam Therapeutics holds a market capitalization between $2.12 billion and $2.23 billion. This valuation underscores its presence in the competitive biotechnology sector. Examining its ownership reveals how founders, early backers, and institutional investors shape its corporate governance and future direction, impacting its Beam Therapeutics Porter's Five Forces Analysis.

Beam Therapeutics was established in 2017 by a group of distinguished scientists in gene editing. The founding team included David R. Liu, J. Keith Joung, Feng Zhang, Nicole Gaudelli, and Alexis Komor. This groundbreaking company emerged from the renowned Broad Institute of MIT and Harvard. While the initial equity distribution among the founders is not publicly disclosed, their collective scientific acumen and pioneering vision for base editing technology formed the foundational intellectual property of the enterprise.

Founding Visionaries

Beam Therapeutics was founded by leading scientists in gene editing, including David R. Liu and Feng Zhang. Their expertise in base editing technology is central to the company's mission.

Origin of Innovation

The company's roots are firmly planted at the Broad Institute of MIT and Harvard. This academic environment fostered the development of its core base editing platform.

Early Capital Infusion

Securing substantial funding was crucial for advancing Beam Therapeutics' innovative approach. Early investment rounds provided the necessary capital for growth and development.

Series A Funding

In May 2018, Beam Therapeutics successfully raised $87 million in its Series A funding round. This round was notably co-led by ARCH Venture Partners and F-Prime Capital Partners.

Series B Financing

A significant Series B financing round on March 6, 2019, brought in $135 million. This funding was critical for expanding the company's operations and research pipeline.

Key Early Investors

Major venture capital firms like ARCH Venture Partners, F-Prime Capital Partners, Redmile Group, LLC, and GV (Google Ventures) were instrumental in early funding. Their support fueled the company's progress.

The early financial backing was pivotal for Beam Therapeutics to propel its novel base editing platform forward. Following its Series A funding of $87 million in May 2018, co-led by ARCH Venture Partners and F-Prime Capital Partners, the company secured an additional $135 million in a Series B financing round on March 6, 2019. This subsequent round saw participation from new investors including Redmile Group, LLC, Cormorant Asset Management, GV (Google Ventures), and Altitude Life Science Ventures, with continued commitment from existing backers like F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, and Omega Funds. These crucial early investments provided the essential capital to expand the team, enhance technological capabilities, and advance the company's therapeutic pipeline towards clinical trials, underscoring the confidence in Beam Therapeutics' potential to address genetic diseases. The company's focus on precision genetic medicine positions it as a key player in the biotechnology sector, with its early investors playing a significant role in its trajectory. Understanding the Competitors Landscape of Beam Therapeutics also highlights the importance of this early strategic funding.

Founders and Intellectual Capital

Beam Therapeutics was founded in 2017 by a team of leading scientists in gene editing. Their collective expertise and vision for base editing technology represent the core intellectual property of the company.

• David R. Liu
• J. Keith Joung
• Feng Zhang
• Nicole Gaudelli
• Alexis Komor

Beam Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Beam Therapeutics transitioned from a private, venture-backed entity to a publicly traded company with its Initial Public Offering (IPO) on February 6, 2020. This significant event marked a shift in its ownership structure, opening the door for broader public investment and changing the landscape of who owns Beam Therapeutics.

As of July 2025, Beam Therapeutics' ownership is predominantly held by institutional investors, reflecting its status as a publicly traded company. The market capitalization hovers between approximately $1.97 billion and $2.23 billion, with 101 million shares outstanding. This indicates a substantial increase in valuation since its IPO, influencing the overall Beam Therapeutics stock ownership.

Major Stakeholders in Beam Therapeutics

Institutional investors are the primary holders of Beam Therapeutics' stock, demonstrating significant confidence in the company's future. Understanding these major shareholders is key to comprehending Beam Therapeutics company ownership.

• Institutional investors hold 100.59% of the company's shares, with 474 entities filing with the SEC as of July 22, 2025.
• Key institutional investors as of March 31, 2025, include Farallon Capital Management LLC, Vanguard Group Inc., ARK Investment Management LLC, BlackRock, Inc., and Fmr LLC.
• Other significant institutional investors comprise Arch Venture Corp, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., and State Street Corp.
• Insiders hold approximately 1.59% of the company's stock.
• Public companies and individual investors collectively hold about 55.23% of the shares.
• CEO John Evans holds 1.99% of the company's shares, valued at $15.6 million as of March 31, 2025.

Beam Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Beam Therapeutics is instrumental in shaping the company's strategic path and upholding strong corporate governance. This board is composed of key figures, including the Chief Executive Officer and independent directors, all contributing diverse expertise to oversee the company's operations and future growth.

The composition of the board reflects a commitment to effective oversight, with John Evans serving as Chief Executive Officer since January 2017. Chirfi Guindo joined the board in December 2024, bringing valuable experience in global biopharmaceutical strategy and commercialization. Graham Cooper, a board member since October 2019, offers significant financial and accounting expertise within the life sciences sector. While specific details regarding dual-class shares or special voting rights are not publicly detailed, the substantial institutional ownership, exceeding 100% of outstanding shares due to factors like short selling, indicates that institutional investors collectively hold considerable voting power. The company's proxy statement for the 2024 Annual Meeting of Stockholders, held on June 5, 2024, confirmed standard voting structures for proposals such as director elections, suggesting a one-share-one-vote system for most shareholder matters.

Understanding Beam Therapeutics' Ownership Structure

The ownership of Beam Therapeutics is primarily shaped by its institutional investors and its board of directors. Understanding who owns Beam Therapeutics is key to grasping its strategic direction.

• Institutional investors hold a significant portion of Beam Therapeutics stock.
• The board of directors guides the company's strategic decisions.
• John Evans is the Chief Executive Officer and a board member.
• Chirfi Guindo's recent appointment enhances global biopharma expertise on the board.
• The company operates under a standard voting structure for most shareholder proposals.

Beam Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Beam Therapeutics has experienced significant shifts in its ownership landscape and strategic direction. As of March 31, 2025, the company maintained a robust financial footing with $1.2 billion in cash, cash equivalents, and marketable securities, bolstered by recent financing rounds that are projected to sustain operations well into 2028.

The company's ownership trends reflect a growing interest from institutional investors, a common pattern in the dynamic biotechnology sector. As of July 22, 2025, a substantial number of institutional owners, totaling 474, collectively held over 117 million shares, indicating confidence in Beam Therapeutics' long-term potential. This increased institutional backing is crucial for companies navigating the high-risk, high-reward environment of gene editing therapies.

Institutional Investor Activity

As of July 22, 2025, 474 institutional owners held more than 117 million shares. This signifies strong backing from investment firms.

Key Hedge Fund Holdings

As of March 31, 2025, notable hedge fund holdings included Farallon Capital Management, L.L.C. with $193.90 million and Ark Investment Management LLC with $165.62 million.

Strategic Collaborations

In January 2022, a significant collaboration was established with Pfizer to advance therapies for rare diseases. This partnership leverages cutting-edge gene editing technologies.

Acquisition for Technology Advancement

The company also acquired Guide Therapeutics, a move that bolsters its capabilities in nonviral drug delivery methods, crucial for therapeutic development. Understanding the Marketing Strategy of Beam Therapeutics provides further insight into its growth trajectory.

Beam Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔